SPOTLIGHT: Avanir gains $42M in drug sale


Avanir has gained $42 million from the sale of its schizophrenia drug FazaClo to Ireland's Azur. The move gives Avanir more money to focus on the development of Zenvia for involuntary emotional expression disorder. Azur also agreed to pay up to $10 million more based on a schedule of sales milestones. Report 

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.